GlassScriptPhysician profile
Sara Elizabeth Ancello
NPI 1720420557
$5,876.36
in general payments reported to CMS, 2019-2025
45 companies · $1,271 in 2025
The $1,271 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $165 · 2020: $121 · 2021: $771 · 2022: $1,484 · 2023: $1,080 · 2024: $985 · 2025: $1,271.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,336.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,336.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,895.70 | 2021-2025 | Rinvoq, Skyrizi, Mavyret |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $660.58 | 2019-2025 | Trulance, Xifaxan, Relistor |
| Pfizer INC. | $578.14 | 2020-2025 | |
| Janssen Biotech, INC. | $279.50 | 2021-2025 | Stelara, Tremfya, Simponi |
| Gilead Sciences, INC. | $168.97 | 2019-2022 | |
| Celgene Corporation | $163.64 | 2019-2024 | Zeposia |
| Medtronic, INC. | $154.76 | 2023 | Interstim |
| Madrigal Pharmaceuticals | $152.08 | 2024-2025 | Rezdiffra, Resmetirom |
| Lilly USA, LLC | $129.21 | 2024-2025 | Omvoh, Zepbound |
| Genzyme Corporation | $123.66 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $119.00 | 2019-2024 | Dupixent |
| Intuitive Surgical, INC. | $116.77 | 2025 | |
| Janssen Scientific Affairs, LLC | $114.30 | 2024 | Stelara |
| Ipsen Biopharmaceuticals, INC | $112.97 | 2025 | Iqirvo |
| Phathom Pharmaceuticals, INC. | $98.36 | 2024-2025 | Voquezna |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $83.58 | 2021-2023 | |
| Boston Scientific Corporation | $78.02 | 2021-2024 | |
| Ambu INC. | $66.85 | 2020 | |
| Pulmonx Corporation | $64.18 | 2025 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Chartis Catheter |
| Abbott Laboratories | $60.41 | 2023-2025 | Proclaim, Freestyle Libre 3 |
| Ferring Pharmaceuticals INC. | $59.46 | 2023-2025 | Rebyota |
| Ironwood Pharmaceuticals, INC | $58.04 | 2021-2022 | |
| Mylan Institutional INC. | $53.54 | 2023 | Hulio |
| Ardelyx, INC. | $50.77 | 2022-2023 | Ibsrela |
| United Therapeutics Corporation | $42.67 | 2021-2024 | Tyvaso |
| Actelion Pharmaceuticals US, INC. | $38.01 | 2022-2024 | Opsumit |
| Takeda Pharmaceuticals U.S.A., INC. | $37.39 | 2023-2024 | Gattex, Eohilia |
| Merck Sharp & Dohme LLC | $32.97 | 2022-2023 | Dificid |
| Fresenius Kabi USA, LLC | $30.52 | 2023 | |
| Biocon Biologics INC | $21.66 | 2025 | Yesintek |
| Celltrion USA INC. | $21.53 | 2025 | Vegzelma |
| Novo Nordisk INC | $19.18 | 2025 | Wegovy |
| Baxter Healthcare | $17.62 | 2023 | Hillrom - Life 2000 Ventilation System |
| Impulse Dynamics (USA) INC. | $16.17 | 2022 | |
| Advanced Respiratory, INC | $15.97 | 2021 | |
| Qol Medical, LLC | $15.72 | 2019 | |
| Amgen INC. | $15.52 | 2025 | Uplizna |
| Redhill Biopharma INC. | $15.35 | 2023 | Talicia |
| Lucid Diagnostics INC. | $15.24 | 2023 | |
| Oxford Immunotec USA INC | $14.46 | 2022 | |
| Axonics, INC. | $14.03 | 2021 | |
| Electromed, INC. | $13.53 | 2025 | Smartvest |
| Shire North American Group INC | $13.51 | 2019 | |
| Allergan, INC. | $11.65 | 2019 | |
| Daiichi Sankyo INC. | $11.17 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Ancello listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.